12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Onfi clobazam regulatory update

FDA issued a drug safety communication and updated the label of Onfi clobazam from H. Lundbeck warning that the seizure drug can cause rare but serious skin reactions, including...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >